A Phase 4 interventional study of Clindamycin and benzoyl peroxide gel (Duac® Topical Gel) and benzoyl peroxide and adapalene gel (EPIDUO™ Gel) in Acne Vulgaris, sponsored by Stiefel, a GSK Company. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-23.
Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.
Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 33rd largest by enrollment, is one of 8 that started in 2009, is one of 16 in phase 4, and was the 10th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:
Centre for Human Drug Research, Netherlands · Sites in Netherlands
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 9 · Phase 4 16
First in 2005; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 117 across the 34 interventional studies. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stiefel, a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Stiefel, a GSK Company is the lead sponsor of 56 studies on the registry; none are open to participants now.
42 studies in Acne Vulgaris by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 42 finished, 24 (57%) have results posted.
Among the 42 studies in Acne Vulgaris by GlaxoSmithKline, this one is the 35th largest by enrollment, is one of 13 that started in 2009, is one of 16 in phase 4, and was the 13th registered.
GlaxoSmithKline’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing clindamycin in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 42 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multi-center, single-blind, randomized, comparative, split-face study. The duration of the study is 8 weeks. Commencing at baseline, subjects will apply once daily both clindamycin and benzoyl peroxide gel and benzoyl peroxide/adapalene gel in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. After visit 3, subjects will commence application of clindamycin and benzoyl peroxide gel to the entire face for an additional 6 weeks.
Multi-center, single-blind, randomized, comparative, split-face study. The duration of the study is 8 weeks and consists of a baseline visit and visits at weeks 1, 2, 5 and 8. Commencing at baseline, subjects will apply once daily both clindamycin and benzoyl peroxide gel and benzoyl peroxide/adapalene gel in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. After visit 3 subjects will commence application of clindamycin and benzoyl peroxide gel to the entire face for an additional 6 weeks.
Blinding This is an investigator-blinded study; therefore, subjects and study-center staff will not be blinded to study treatment allocation (ie, left vs. right side application). During the first 2 weeks, the investigator will be unaware of which study product is being used on either side of the face. Subjects and study-center staff will be instructed not to reveal study treatment allocation to the investigator. Subjects will be instructed not to use study product in the presence of the investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
Drug: Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)
Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
Drug: benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
Drug pages: Clindamycin · Benzoyl Peroxide
Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
Also known as: Duac® Topical Gel
Drug pages: Benzoyl Peroxide · Adapalene
Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
Also known as: EPIDUO™ Gel
Skin Dryness Score
Investigator assessment of tolerability (skin dryness) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Week 1, Week 2
Skin Peeling Score
Investigator assessment of tolerability (skin peeling) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; Intense, 3.
Time frame: Week 1, Week 2
Irritant/Allergic Contact Dermatitis Score
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis) on the face. Erythema,peeling, and dryness were graded using the following scale: 0 None 1. Slight 2. Moderate 3. Intense
Time frame: Week 1, Week 2
Erythema (Redness) Score
Investigator assessment of tolerability (irritant/allergic contact dermatitis) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Week 1, Week 2
Erythema (Redness) Score
Investigator assessment of tolerability (erythema) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Week 5, Week 8
Skin Dryness Score
Investigator assessment of tolerability (skin dryness) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Week 5, Week 8
Skin Peeling Score
Investigator assessment of tolerability (skin peeling) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Week 5, Week 8
Irritant/Allergic Contact Dermatitis Score
Investigator assessment of tolerability (contact dermatitis) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Week 5, Week 8
Investigator Static Global Assessment Score
ISGA is evaluated using the following scale: 0, clear, clear skin with no lesions; 1, almost clear, rare non-inflammatory lesions; 2, mild, some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions; 3, moderate, up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, severe, up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, very severe, many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.
Time frame: Week 5, Week 8
Inflammatory Acne Lesion Counts
Total number of inflammatory acne lesions (pustules, papules) at each timepoint.
Time frame: Week 5, Week 8
Non-Inflammatory Acne Lesion Counts
Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.
Time frame: Week 5, Week 8
Total Acne Lesion Counts
Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),
Time frame: Week 5, Week 8
Skindex-29 Quality of Life Questionnaire - Symptomatic Domain
Skindex-29 Quality of Life (QoL) Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: "never" to "all the time", higher scores for each domain indicate worse effects on QoL. Scores range from 0 to 100. Higher scores indicate worse QoL for that domain.
Time frame: Baseline, and Week 8
Skindex-29 Quality of Life Questionnaire - Emotional Domain
Skindex-29 Quality of Life (QoL)Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: "never" to "all the time", higher scores for each domain indicate worse effects on QoL. Scores range from 0 to 100. Higher scores indicate worse QoL for that domain.
Time frame: Baseline, and Week 8
Skindex-29 Quality of Life Questionnaire - Functional Domain
Skindex-29 Quality of Life (QoL)Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: "never" to "all the time", higher scores for each domain indicate worse effects on QoL. Scores range from 0 to 100. Higher scores indicate worse QoL for that domain.
Time frame: Baseline, and Week 8
Skindex-29 Quality of Life Questionnaire - Global Score
Skindex-29 Quality of Life (QoL)Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: "never" to "all the time", higher scores for each domain indicate worse effects on QoL. The Global Score ranges from 0 to 100. Higher scores indicate worse QoL for that domain.
Time frame: Baseline, and Week 8
Product Acceptability and Preference Questionnaire - Severity of Redness
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Severity of Redness
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Severity of Dryness
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Severity of Dryness
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Severity of Burning
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Severity of Burning
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Severity of Itching
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Severity of Itching
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Severity of Scaling
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Severity of Scaling
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Ease of Application of Product
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, very easy; 2, easy; 3, neutral; 4, difficult; 5, very difficult.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Ease of Application of Product
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, very easy; 2, easy; 3, neutral; 4, difficult; 5, very difficult.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Comfort of Skin
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, very comfortable; 2, comfortable; 3, somewhat comfortable; 4, somewhat uncomfortable; 5, uncomfortable.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Comfort of Skin
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, very comfortable; 2, comfortable; 3, somewhat comfortable; 4, somewhat uncomfortable; 5, uncomfortable.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With?
Product Acceptability and Preference Questionnaire was completed by the subject at week 1 and week 2 asking which study product they were more satisfied with: Duac or Epiduo.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Comparison of Study Products to Products Used in the Past
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, more satisfied; 2, somewhat more satisfied; 3, neither satisfied or dissatisfied; 4, more satisfied; 5, more dissatisfied.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, highly favorable; 2, favorable; 3, neutral; 4, unfavorable; 5, highly unfavorable.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, highly favorable; 2, favorable; 3, neutral; 4, unfavorable; 5, highly unfavorable.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Compliance
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, non-compliant (\< 50% of the week); 1, mostly compliant (50-79%); 2, very compliant (80-100%).
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Compliance
Subject response to question regarding use of the product every day or not at week 8 time point answering Yes or No
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin
Subject response to question: did you feel that your skin was hydrated and moisturized while you on your study product? (Yes or No).
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin
Subject response to question: did you feel that your skin was hydrated and moisturized while you on your study product? (Yes or No).
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment
Subject response to the following question: If you were to choose to continue treatment for your acne, which treatment would you choose? (Yes or No).
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment
Subject response to the following question: If you were to choose to continue treatment for your acne, which treatment would you choose? (Yes or No).
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, not applicable; 1, very easy; 2, easy; 3, neutral; 4, difficult.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up
Measure Description Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, not applicable; 1, very easy; 2, easy; 3, neutral; 4, difficult.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, very satisfied; 2, satisfied; 3, neutral; 4, unsatisfied; 5, very unsatisfied.
Time frame: Week 1, Week 2
Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, very satisfied; 2, satisfied; 3, neutral; 4, unsatisfied; 5, very unsatisfied.
Time frame: Week 8
Clinical research centers
| Milestone | All Study Participants |
|---|---|
| Started | 28 |
| Completed | 28 |
| Not completed | 0 |
| Milestone | All Study Participants |
|---|---|
| Started | 28 |
| Completed | 27 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
Investigator assessment of tolerability (skin dryness) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.15 ± 0.37 | 0.46 ± 0.71 |
| Week 2 | 0.14 ± 0.36 | 0.29 ± 0.53 |
Investigator assessment of tolerability (skin peeling) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; Intense, 3.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.15 ± 0.37 | 0.54 ± 0.71 |
| Week 2 | 0.18 ± 0.39 | 0.21 ± 0.50 |
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis) on the face. Erythema,peeling, and dryness were graded using the following scale: 0 None 1. Slight 2. Moderate 3. Intense
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.00 ± 0.00 | 0.15 ± 0.46 |
| Week 2 | 0.00 ± 0.00 | 0.00 ± 0.00 |
Investigator assessment of tolerability (irritant/allergic contact dermatitis) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.27 ± 0.53 | 0.58 ± 0.81 |
| Week 2 | 0.18 ± 0.39 | 0.36 ± 0.49 |
Investigator assessment of tolerability (erythema) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| Units on a scale | Duac Gel |
|---|---|
| Week 5 | 0.26 ± 0.53 |
| Week 8 | 0.19 ± 0.40 |
Investigator assessment of tolerability (skin dryness) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| Units on a scale | Duac Gel |
|---|---|
| Week 5 | 0.15 ± 0.46 |
| Week 8 | 0.00 ± 0.00 |
Investigator assessment of tolerability (skin peeling) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| Units on a scale | Duac Gel |
|---|---|
| Week 5 | 0.00 ± 0.00 |
| Week 8 | 0.00 ± 0.00 |
Investigator assessment of tolerability (contact dermatitis) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| Units on a scale | Duac Gel |
|---|---|
| Week 5 | 0.04 ± 0.19 |
| Week 8 | 0.00 ± 0.00 |
ISGA is evaluated using the following scale: 0, clear, clear skin with no lesions; 1, almost clear, rare non-inflammatory lesions; 2, mild, some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions; 3, moderate, up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, severe, up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, very severe, many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.
| Units on a scale | Duac Gel |
|---|---|
| Week 5 | 2.63 ± 0.93 |
| Week 8 | 2.15 ± 1.03 |
Total number of inflammatory acne lesions (pustules, papules) at each timepoint.
| inflammatory acne lesions | Duac Gel |
|---|---|
| Week 5 | 8.44 ± 7.57 |
| Week 8 | 7.00 ± 9.03 |
Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.
| non-inflammatory acne lesions | Duac Gel |
|---|---|
| Week 5 | 14.37 ± 11.20 |
| Week 8 | 10.81 ± 8.88 |
Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),
| total acne lesions | Duac Gel |
|---|---|
| Week 5 | 22.81 ± 14.87 |
| Week 8 | 17.81 ± 14.04 |
Skindex-29 Quality of Life (QoL) Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: "never" to "all the time", higher scores for each domain indicate worse effects on QoL. Scores range from 0 to 100. Higher scores indicate worse QoL for that domain.
| Units on a scale | Duac Gel |
|---|---|
| Baseline | 28.10 ± 17.01 |
| Week 8 | 21.72 ± 11.60 |
Skindex-29 Quality of Life (QoL)Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: "never" to "all the time", higher scores for each domain indicate worse effects on QoL. Scores range from 0 to 100. Higher scores indicate worse QoL for that domain.
| Units on a scale | Duac Gel |
|---|---|
| Baseline | 44.29 ± 28.03 |
| Week 8 | 35.37 ± 26.03 |
Skindex-29 Quality of Life (QoL)Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: "never" to "all the time", higher scores for each domain indicate worse effects on QoL. Scores range from 0 to 100. Higher scores indicate worse QoL for that domain.
| Units on a scale | Duac Gel |
|---|---|
| Baseline | 14.06 ± 13.41 |
| Week 8 | 9.10 ± 10.39 |
Skindex-29 Quality of Life (QoL)Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: "never" to "all the time", higher scores for each domain indicate worse effects on QoL. The Global Score ranges from 0 to 100. Higher scores indicate worse QoL for that domain.
| Units on a scale | Duac Gel |
|---|---|
| Baseline | 14.06 ± 13.41 |
| Week 8 | 9.10 ± 10.39 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.12 ± 1.24 | 1.54 ± 1.36 |
| Week 2 | 0.78 ± 0.80 | 1.00 ± 0.89 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Redness | 1.00 ± 1.14 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.42 ± 1.36 | 1.88 ± 1.82 |
| Week 2 | 1.31 ± 1.23 | 1.58 ± 1.27 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Dryness | 1.22 ± 1.12 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.12 ± 1.24 | 1.96 ± 1.61 |
| Week 2 | 0.73 ± 0.92 | 1.11 ± 1.31 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Burning | 0.63 ± 0.93 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.19 ± 1.13 | 1.42 ± 1.30 |
| Week 2 | 0.81 ± 1.02 | 1.19 ± 1.27 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Itching | 0.63 ± 1.01 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.77 ± 1.07 | 1.15 ± 1.32 |
| Week 2 | 0.69 ± 0.93 | 1.00 ± 1.17 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Scaling | 0.78 ± 1.28 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, very easy; 2, easy; 3, neutral; 4, difficult; 5, very difficult.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.46 ± 0.58 | 1.50 ± 0.71 |
| Week 2 | 1.43 ± 0.50 | 1.50 ± 0.84 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, very easy; 2, easy; 3, neutral; 4, difficult; 5, very difficult.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Ease of Application of Product | 1.26 ± 0.45 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, very comfortable; 2, comfortable; 3, somewhat comfortable; 4, somewhat uncomfortable; 5, uncomfortable.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 2.38 ± 0.94 | 2.58 ± 1.24 |
| Week 2 | 2.00 ± 0.86 | 2.25 ± 1.14 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, very comfortable; 2, comfortable; 3, somewhat comfortable; 4, somewhat uncomfortable; 5, uncomfortable.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Comfort of Skin | 1.78 ± 0.85 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 1 and week 2 asking which study product they were more satisfied with: Duac or Epiduo.
| Participants | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 17 | 8 |
| Week 2 | 12 | 15 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, more satisfied; 2, somewhat more satisfied; 3, neither satisfied or dissatisfied; 4, more satisfied; 5, more dissatisfied.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Comparison of Study Products to Products Used in the Past | 1.93 ± 1.24 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, highly favorable; 2, favorable; 3, neutral; 4, unfavorable; 5, highly unfavorable.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 2.27 ± 0.78 | 2.27 ± 0.72 |
| Week 2 | 2.14 ± 0.80 | 2.07 ± 0.81 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, highly favorable; 2, favorable; 3, neutral; 4, unfavorable; 5, highly unfavorable.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products | 2.07 ± 1.14 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, non-compliant (\< 50% of the week); 1, mostly compliant (50-79%); 2, very compliant (80-100%).
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.96 ± 0.20 | 1.93 ± 0.20 |
| Week 2 | 1.93 ± 0.26 | 1.93 ± 0.26 |
Subject response to question regarding use of the product every day or not at week 8 time point answering Yes or No
| Participants | Duac Gel |
|---|---|
| Yes | 24 |
| No | 3 |
Subject response to question: did you feel that your skin was hydrated and moisturized while you on your study product? (Yes or No).
| Participants | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 - Yes | 18 | 16 |
| Week 1 - No | 8 | 10 |
| Week 2 - Yes | 19 | 18 |
| Week 2 - No | 8 | 9 |
Subject response to question: did you feel that your skin was hydrated and moisturized while you on your study product? (Yes or No).
| Participants | Duac Gel |
|---|---|
| Yes | 24 |
| No | 3 |
Subject response to the following question: If you were to choose to continue treatment for your acne, which treatment would you choose? (Yes or No).
| Participants | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 - Yes | 19 | 15 |
| Week 1 - No | 5 | 10 |
| Week 2 - Yes | 16 | 18 |
| Week 2 - No | 10 | 9 |
Subject response to the following question: If you were to choose to continue treatment for your acne, which treatment would you choose? (Yes or No).
| Participants | Duac Gel |
|---|---|
| Yes | 20 |
| No | 7 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, not applicable; 1, very easy; 2, easy; 3, neutral; 4, difficult.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 2.31 ± 1.11 | 2.38 ± 1.12 |
| Week 2 | 1.59 ± 0.87 | 1.59 ± 0.87 |
Measure Description Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, not applicable; 1, very easy; 2, easy; 3, neutral; 4, difficult.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up | 1.89 ± 0.96 |
Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, very satisfied; 2, satisfied; 3, neutral; 4, unsatisfied; 5, very unsatisfied.
| Units on a scale | Duac Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 2.04 ± 0.92 | 2.19 ± 1.06 |
| Week 2 | 2.21 ± 1.17 | 2.32 ± 1.16 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, very satisfied; 2, satisfied; 3, neutral; 4, unsatisfied; 5, very unsatisfied.
| Units on a scale | Duac Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product | 2.52 ± 1.37 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Study Participants | — | 0/28 (0%) | 0/28 (0%) |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 29.6 ± 9.5 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 24 |
| Male | 4 |
| Race/Ethnicity, Customized(Participants) | All Study Participants |
|---|---|
| Asian | 2 |
| Black or African American | 11 |
| White | 15 |
| Region of Enrollment(participants) | All Study Participants |
|---|---|
| United States | 28 |
| Investigators Static Global Assessment (ISGA)(Participants) | All Study Participants |
|---|---|
| Mild | 2 |
| Moderate | 20 |
| Severe | 6 |
| Inflammatory Acne Lesion Count(Inflammatory Lesion) | All Study Participants |
|---|---|
| Mean | 21.5 ± 9.3 |
| Non-Inflammatory Acne Lesion Count(Non-Inflammatory lesion) | All Study Participants |
|---|---|
| Mean | 33.0 ± 24.7 |
| Total Acne Lesion Count(Acne lesions) | All Study Participants |
|---|---|
| Mean | 54.5 ± 27.1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jul 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide